PTC Therapeutics has received FDA approval for a gene therapy to treat AADC deficiency, a rare genetic disorder that impairs ...

The global contract development and manufacturing organization ​ (CDMO), Samsung Biologics, announced this week that it has ...

Finally, the number of opportunities in the biosimilars space is very high — there are more than 300 biologics in the market, ...

The interim phase 2 trial results show a good immune response in participants and the therapy is well tolerated to date.

Collaboration to leverage Steritas’ STOX Suite in developing innovative treatments for autoimmune diseases.

Alentis’ Series D financing round this week, marks the largest ADC-related fundraising in Europe in 2024. Other notable ...

From developing treatments for Ebola to mastering karate with her daughters, Dr. Helen Harrington’s journey is one of ...

A serious adverse event in the New York biotech’s phase 1/2 trial of its Rett syndrome gene therapy puts a question mark over ...

New cGMP fermentation facility in the UK set to meet growing demand for drug substance production, supporting biopharma ...

Emraclidine was expected to be a competitor to Bristol Myers Squibb’s recently approved Cobenfy, but trial results put its ...

The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient. The U.S.

Steritas LLC, a Boston-based company committed to improving care for patients treated with steroids, has announced a multi-year licensing agreement with argenx, a global leader in immunology. The ...